Bill > HR9142

This bill, the Responsibility in Drug Advertising Act of 2024, aims to restrict direct-to-consumer (DTC) drug advertising. The key provisions are: 1. A 3-year ban on DTC advertising, including on social media platforms, for drugs newly approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act, with a potential waiver in the third year if the Secretary of Health and Human Services determines the advertising would have a positive impact on public health. 2. The Secretary may prohibit DTC advertising, including on social media, for a drug after the initial 3-year period if significant adverse health effects are identified based on post-approval studies, risk-benefit analyses, adverse event reports, or other relevant information. 3. The Secretary is required to revise existing regulations governing drug advertisements within 1 year to implement these new restrictions. 4. The bill clarifies that these provisions do not diminish the Secretary's existing authority to regulate or prohibit DTC drug advertising under other applicable laws.